Welcome to Mind the Gap!

I’m Nita Jain, a scientist, biotech founder, patient advocate, and someone who has spent a long time in the gaps.

My background is in systems biology and network medicine. I think in networks, not pathways, which means I’m drawn to the areas in which the standard reductionist model breaks down, the textbook presentation doesn’t match the patient in front of you, and the framework designed for acute disease breaks down in the face of complex chronic diseases.

I’m the Founder and CEO of Timeless Biosciences, where I’m developing microbiome-based therapeutics for chemotherapy-resistant colorectal cancer.

I serve on advisory committees for the NIH RECOVER Initiative and the Emory REVERSE-LC Community Advisory Board, working alongside researchers and clinicians to shape how post-infectious illnesses are studied.

I built The Spooniverse, a comprehensive reference platform for complex chronic illness because full-time patients shouldn’t have to struggle to find resources they need. I’m also building Fig Health, a telehealth practice for patients who already know their bodies and just need a physician who believes them.

Mind the Gap is where I think out loud.

The tagline comes from the London Underground, that warning to watch the space between the train and the platform. In healthcare, that gap is everywhere, and it’s rarely accidental.

There’s the gap between what research discovers and what reaches patients, often measured in decades that people simply don’t have. There’s the gap between what patients experience and what medicine can measure, and when those diverge, the system has a troubling habit of concluding the problem is the patient.

There’s the gap between the biological complexity of chronic illnesses and the reductionist frameworks we use to study them. There’s the gap between what institutions promise and what they deliver.

I cover the science, the politics, and the structural failures. Microbiome research and its very real limitations. Mitochondrial biology and chronic disease. The economics of drug development. I do my best to hold complexity without collapsing it, provide nuance without losing the thread, and name uncertainty rather than project false confidence.

I’m not here to tell you what to think but to show you what’s being left out of the conversation.

Join the Community!

Subscribe to get access to the newsletter, podcast, and blog. Each edition goes straight to your inbox, but please check your “Promotions” folder and drag the email to your “Primary” folder if you’re unable to find it.

Free subscribers receive the core newsletter. Paid subscribers also receive access to:

The Patient Perspective: A recurring series examining firsthand accounts and case studies where medicine got it wrong, what the failure reveals about the system, and what should have happened instead. These are the cases that don’t make it into grand rounds.

Liner Notes: Deep dives on topics that fifteen-minute appointments can’t cover and the internet tends to get wrong. Current and forthcoming topics include the limitations of microbiome testing, what patients and caregivers need to know about cancer biology, and mitochondrial health beyond the wellness noise.

Subscriber Chat: Direct access to ask questions and discuss concerns.